These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 14513056)

  • 21. Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission.
    Potenza L; Luppi M; Riva G; Marasca R; Martinelli S; Torelli G
    Haematologica; 2005 Sep; 90(9):1275-7. PubMed ID: 16154854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Disease transformation in imatinib mesylate treated Philadelphia chromosome-positive chronic myelogenous leukemia patients achieved cytogenetic remissions].
    Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Lu DP
    Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 37(6):612-5. PubMed ID: 16378113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myelodysplastic features developing in Philadephia-negative cells during imatinib mesylate therapy for CML: report of a new case.
    Mozziconacci MJ; Caillères S; Maurice C; Vey N; Sainty D; Blaise D; Lafage-Pochitaloff M
    Leukemia; 2003 Sep; 17(9):1901-2. PubMed ID: 12970792
    [No Abstract]   [Full Text] [Related]  

  • 24. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate.
    O'Dwyer ME; Gatter KM; Loriaux M; Druker BJ; Olson SB; Magenis RE; Lawce H; Mauro MJ; Maziarz RT; Braziel RM
    Leukemia; 2003 Mar; 17(3):481-7. PubMed ID: 12646934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imatinib mesylate--a new oral targeted therapy.
    Savage DG; Antman KH
    N Engl J Med; 2002 Feb; 346(9):683-93. PubMed ID: 11870247
    [No Abstract]   [Full Text] [Related]  

  • 26. Isodicentric Philadelphia chromosomes in imatinib mesylate (Gleevec)-resistant patients.
    Szych CM; Liesveld JL; Iqbal MA; Li L; Siebert S; Asmus C; O'Malley J; Lee A; Wang N
    Cancer Genet Cytogenet; 2007 Apr; 174(2):132-7. PubMed ID: 17452255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.
    Kolb EA; Pan Q; Ladanyi M; Steinherz PG
    Cancer; 2003 Dec; 98(12):2643-50. PubMed ID: 14669284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The first case of Philadelphia chromosome-negative acute promyelocytic leukemia following imatinib for chronic myelogenous leukemia.
    Wakim JJ; Tirado CA; Dowell J; Chen W
    Cancer Genet; 2012 Mar; 205(3):124-7. PubMed ID: 22469511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imatinib achieved complete cytogenetic response in a CML patient received 32-year indirubin and its derivative treatment.
    Chen F; Li L; Ma D; Yan S; Sun J; Zhang M; Ji C; Hou M
    Leuk Res; 2010 Feb; 34(2):e75-7. PubMed ID: 19773083
    [No Abstract]   [Full Text] [Related]  

  • 30. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
    Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of acute myeloid leukemia with NPM1 mutation, in Ph-negative clone, during treatment of CML with imatinib.
    Georgiou G; Efthymiou A; Vardounioti I; Boutsikas G; Angelopoulou MK; Vassilakopoulos TP; Kyrtsonis MC; Plata E; Tofas P; Bitsani A; Bartzi V; Pessach I; Dimou M; Panayiotidis P
    Leukemia; 2012 Apr; 26(4):824-6. PubMed ID: 21986839
    [No Abstract]   [Full Text] [Related]  

  • 33. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imatinib for relapsed BCR/ABL positive leukemias.
    Ottmann OG; Wassmann B; Hoelzer D
    Ann Hematol; 2002; 81 Suppl 2():S36-7. PubMed ID: 12611069
    [No Abstract]   [Full Text] [Related]  

  • 35. Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR.
    Hui CH; Goh KY; White D; Branford S; Grigg A; Seymour JF; Kwan YL; Walsh S; Hoyt R; Trickett A; Rudzki B; Ma DD; To LB; Hughes TP
    Leukemia; 2003 May; 17(5):821-8. PubMed ID: 12750692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imatinib mesylate: A designer drug.
    Panigrahi I; Naithani R
    J Assoc Physicians India; 2006 Mar; 54():203-6. PubMed ID: 16800347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diminished alpha2-plasmin inhibitor activity associated with the use of imatinib mesylate in patients with Philadelphia chromosome-positive haematologic cancer.
    Matsue K; Matsuo K; Fujiwara H; Iwama K; Hayama BY; Kimura S; Yamakura M; Takeuch M
    Thromb Haemost; 2009 Jun; 101(6):1170-1. PubMed ID: 19492163
    [No Abstract]   [Full Text] [Related]  

  • 38. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias.
    Shimoni A; Kröger N; Zander AR; Rowe JM; Hardan I; Avigdor A; Yeshurun M; Ben-Bassat I; Nagler A
    Leukemia; 2003 Feb; 17(2):290-7. PubMed ID: 12592325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
    Kantarjian H; Sawyers C; Hochhaus A; Guilhot F; Schiffer C; Gambacorti-Passerini C; Niederwieser D; Resta D; Capdeville R; Zoellner U; Talpaz M; Druker B; Goldman J; O'Brien SG; Russell N; Fischer T; Ottmann O; Cony-Makhoul P; Facon T; Stone R; Miller C; Tallman M; Brown R; Schuster M; Loughran T; Gratwohl A; Mandelli F; Saglio G; Lazzarino M; Russo D; Baccarani M; Morra E;
    N Engl J Med; 2002 Feb; 346(9):645-52. PubMed ID: 11870241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; Cortes J; O'Brien S; Faderl S; Thomas D; Giles F; Rios MB; Shan J; Arlinghaus R
    Clin Cancer Res; 2003 Jan; 9(1):160-6. PubMed ID: 12538464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.